{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:30:14Z","timestamp":1764325814825,"version":"3.46.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID","PIA\/ANR-16-CONV-0005","ANR-10-LABX-62-IBEID","PIA\/ANR-16-CONV-0005"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID","PIA\/ANR-16-CONV-0005","ANR-10-LABX-62-IBEID","PIA\/ANR-16-CONV-0005"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine research institute","award":["ANR-10-LABX-77"],"award-info":[{"award-number":["ANR-10-LABX-77"]}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["DURABLE grant 101102733","RECOVER 101003589"],"award-info":[{"award-number":["DURABLE grant 101102733","RECOVER 101003589"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["URGENCE COVID-19"],"award-info":[{"award-number":["URGENCE COVID-19"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this cohort study, we aimed to study the risk of SARS-CoV-2 infection and its association with household exposure, as well as demographic and health factors. Between March 2020 and April 2022, we conducted a cohort study among adults and children aged 5 years or more in a town in northern France. Participants were screened repeatedly for post-infection anti-SARS-CoV-2 immunity. Infection dates were inferred in hierarchical order from symptomatic episodes or virological tests, or if unavailable from the timing of other cases in the household or the window of seroconversion. Household exposure to a case of SARS-CoV-2 during the infectious phase was defined as a time-varying exposure. We included 830 participants with a mean follow-up of 453 days (12,353 total person-months), during which we identified 491 infections (incidence rate 39.7 per 1,000 person-months). In adjusted analyses, exposure in the household to an infected individual was associated with an incidence rate ratio (IRR) of 16.48 (95% CI 12.29\u201322.09), and baseline statin use was associated with a decreased risk of infection (IRR 0.35, 95% CI 0.13\u20130.89). These results could contribute to the development of additional prophylactic strategies, e.g., post-exposure, for the population at high risk of severe forms of COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-025-26851-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:25:51Z","timestamp":1764325551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France"],"prefix":"10.1038","volume":"15","author":[{"given":"Simon","family":"Galmiche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Pinaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tondeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Pelleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika\u00ebl","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Castelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Duru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymar Davy","family":"Koffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Fernandes-Pellerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Fontanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26851_CR1","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1093\/cid\/ciab100","volume":"73","author":"HA Thompson","year":"2021","unstructured":"Thompson, H. A. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Setting-specific transmission rates: A systematic review and Meta-analysis. Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am. 73, e754\u2013e764 (2021).","journal-title":"Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am."},{"key":"26851_CR2","doi-asserted-by":"publisher","first-page":"e2031756","DOI":"10.1001\/jamanetworkopen.2020.31756","volume":"3","author":"ZJ Madewell","year":"2020","unstructured":"Madewell, Z. J., Yang, Y., Longini, I. M., Halloran, M. E. & Dean, N. E. Household transmission of SARS-CoV-2: A systematic review and Meta-analysis. JAMA Netw. Open. 3, e2031756 (2020).","journal-title":"JAMA Netw. Open."},{"key":"26851_CR3","doi-asserted-by":"publisher","first-page":"e229317","DOI":"10.1001\/jamanetworkopen.2022.9317","volume":"5","author":"ZJ Madewell","year":"2022","unstructured":"Madewell, Z. J., Yang, Y., Longini, I. M., Halloran, M. E. & Dean, N. E. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and Meta-analysis. JAMA Netw. Open. 5, e229317 (2022).","journal-title":"JAMA Netw. Open."},{"key":"26851_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12889-024-17772-y","volume":"24","author":"A Rakover","year":"2024","unstructured":"Rakover, A. et al. Source of SARS-CoV-2 infection: results from a series of 584,846 cases in France from October 2020 to August 2022. BMC Public. Health. 24, 325 (2024).","journal-title":"BMC Public. Health"},{"key":"26851_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tim.2015.10.012","volume":"24","author":"TK Tsang","year":"2016","unstructured":"Tsang, T. K., Lau, L. L. H., Cauchemez, S. & Cowling, B. J. Household transmission of influenza virus. Trends Microbiol. 24, 123\u2013133 (2016).","journal-title":"Trends Microbiol."},{"key":"26851_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2021.07.037","volume":"83","author":"E Miller","year":"2021","unstructured":"Miller, E. et al. Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. J. Infect. 83, 483\u2013489 (2021).","journal-title":"J. Infect."},{"key":"26851_CR7","doi-asserted-by":"publisher","first-page":"e210304","DOI":"10.1001\/jamanetworkopen.2021.0304","volume":"4","author":"JP Metlay","year":"2021","unstructured":"Metlay, J. P., Haas, J. S., Soltoff, A. E. & Armstrong, K. A. Household transmission of SARS-CoV-2. JAMA Netw. Open. 4, e210304 (2021).","journal-title":"JAMA Netw. Open."},{"key":"26851_CR8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/cid\/ciab186","volume":"73","author":"LA Paul","year":"2021","unstructured":"Paul, L. A. et al. Characteristics associated with household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Ontario, canada: A cohort study. Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am. 73, 1840\u20131848 (2021).","journal-title":"Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am."},{"key":"26851_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"K Koushki","year":"2021","unstructured":"Koushki, K. et al. Anti-inflammatory action of Statins in cardiovascular disease: the role of inflammasome and Toll-Like receptor pathways. Clin. Rev. Allergy Immunol. 60, 175\u2013199 (2021).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"26851_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7150\/ijms.51935","volume":"18","author":"P Ho","year":"2021","unstructured":"Ho, P. et al. Perspective adjunctive therapies for COVID-19: beyond antiviral therapy. Int. J. Med. Sci. 18, 314\u2013324 (2021).","journal-title":"Int. J. Med. Sci."},{"key":"26851_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-021-21553-1","volume":"12","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Association between antecedent Statin use and decreased mortality in hospitalized patients with COVID-19. Nat. Commun. 12, 1325 (2021).","journal-title":"Nat. Commun."},{"key":"26851_CR12","doi-asserted-by":"publisher","first-page":"e023357","DOI":"10.1161\/JAHA.121.023357","volume":"11","author":"K Bouillon","year":"2022","unstructured":"Bouillon, K. et al. Association of Statins for primary prevention of cardiovascular diseases with hospitalization for COVID-19: A nationwide matched Population\u2010Based cohort study. J. Am. Heart Assoc. 11, e023357 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"26851_CR13","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMoa2309995","volume":"389","author":"REMAPCAP Investigators","year":"2023","unstructured":"Investigators, R. E. M. A. P. C. A. P. et al. Simvastatin in critically ill patients with Covid-19. N Engl. J. Med. 389, 2341\u20132354 (2023).","journal-title":"N Engl. J. Med."},{"key":"26851_CR14","first-page":"e068407","volume":"376","author":"INSPIRATIONS Investigators","year":"2022","unstructured":"Investigators, I. N. S. P. I. R. A. T. I. O. N. S. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ 376, e068407 (2022).","journal-title":"BMJ"},{"key":"26851_CR15","doi-asserted-by":"publisher","first-page":"e28971","DOI":"10.1002\/jmv.28971","volume":"95","author":"I Visos-Varela","year":"2023","unstructured":"Visos-Varela, I. et al. Outpatient Atorvastatin use and severe COVID-19 outcomes: A population-based study. J. Med. Virol. 95, e28971 (2023).","journal-title":"J. Med. Virol."},{"key":"26851_CR16","doi-asserted-by":"publisher","first-page":"12047","DOI":"10.1038\/s41598-022-16357-2","volume":"12","author":"A Santosa","year":"2022","unstructured":"Santosa, A. et al. Protective effects of Statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study. Sci. Rep. 12, 12047 (2022).","journal-title":"Sci. Rep."},{"key":"26851_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/jpm11020116","volume":"11","author":"TK Oh","year":"2021","unstructured":"Oh, T. K., Song, I. A. & Jeon, Y. T. Statin therapy and the risk of COVID-19: A cohort study of the National health insurance service in South Korea. J. Pers. Med. 11, 116 (2021).","journal-title":"J. Pers. Med."},{"key":"26851_CR18","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2666-5247(23)00005-8","volume":"4","author":"S Galmiche","year":"2023","unstructured":"Galmiche, S. et al. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in france: a case series analysis from the ComCor study. Lancet Microbe. 4, e409\u2013e417 (2023).","journal-title":"Lancet Microbe"},{"key":"26851_CR19","doi-asserted-by":"crossref","unstructured":"Fontanet, A. et al. SARS-CoV-2 infection in schools in a Northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Euro Surveill 26, (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.15.2001695"},{"key":"26851_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/infdis\/jiab375","volume":"224","author":"S Pelleau","year":"2021","unstructured":"Pelleau, S. et al. Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological Estimation of time since infection. J. Infect. Dis. 224, 1489\u20131499 (2021).","journal-title":"J. Infect. Dis."},{"key":"26851_CR21","doi-asserted-by":"publisher","first-page":"2200681","DOI":"10.2807\/1560-7917.ES.2023.28.25.2200681","volume":"28","author":"T Woudenberg","year":"2023","unstructured":"Woudenberg, T. et al. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. Eurosurveillance 28, 2200681 (2023).","journal-title":"Eurosurveillance"},{"key":"26851_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/eji.202049058","volume":"51","author":"F Anna","year":"2021","unstructured":"Anna, F. et al. High Seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Eur. J. Immunol. 51, 180\u2013190 (2021).","journal-title":"Eur. J. Immunol."},{"key":"26851_CR23","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1038\/s41467-020-17317-y","volume":"11","author":"CH GeurtsvanKessel","year":"2020","unstructured":"GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat. Commun. 11, 3436 (2020).","journal-title":"Nat. Commun."},{"key":"26851_CR24","doi-asserted-by":"publisher","first-page":"e0028821","DOI":"10.1128\/JCM.00288-21","volume":"59","author":"E English","year":"2021","unstructured":"English, E. et al. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of Concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. J. Clin. Microbiol. 59, e0028821 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"26851_CR25","doi-asserted-by":"publisher","first-page":"eabc3103","DOI":"10.1126\/scitranslmed.abc3103","volume":"12","author":"L Grzelak","year":"2020","unstructured":"Grzelak, L. et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci. Transl Med. 12, eabc3103 (2020).","journal-title":"Sci. Transl Med."},{"key":"26851_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S2213-2600(22)00226-0","volume":"10","author":"S Hakki","year":"2022","unstructured":"Hakki, S. et al. Onset and window of SARS-CoV-2 infectiousness and Temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir Med. 10, 1061\u20131073 (2022).","journal-title":"Lancet Respir Med."},{"key":"26851_CR27","unstructured":"Sant\u00e9 Publique France. Enqu\u00eates Flash: \u00e9valuation de la circulation des variants du SARS-CoV-2 en France. https:\/\/www.santepubliquefrance.fr\/etudes-et-enquetes\/enquetes-flash-evaluation-de-la-circulation-des-variants-du-sars-cov-2-en-france"},{"key":"26851_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12879-021-05864-8","volume":"21","author":"F Carrat","year":"2021","unstructured":"Carrat, F. et al. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infect. Dis. 21, 169 (2021).","journal-title":"BMC Infect. Dis."},{"key":"26851_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12879-023-08257-1","volume":"23","author":"S Vaux","year":"2023","unstructured":"Vaux, S., Gautier, A., Soullier, N. & Levy-Bruhl, D. SARS-CoV-2 testing, infection and places of contamination in France, a National cross-sectional study, December 2021. BMC Infect. Dis. 23, 279 (2023).","journal-title":"BMC Infect. Dis."},{"key":"26851_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s15010-021-01731-5","volume":"50","author":"F Carrat","year":"2022","unstructured":"Carrat, F. et al. COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. Infection 50, 257\u2013262 (2022).","journal-title":"Infection"},{"key":"26851_CR31","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/ntr\/ntab004","volume":"23","author":"N Paleiron","year":"2021","unstructured":"Paleiron, N. et al. Impact of tobacco smoking on the risk of COVID-19: A large scale retrospective cohort study. Nicotine Tob. Res. Off J. Soc. Res. Nicotine Tob. 23, 1398\u20131404 (2021).","journal-title":"Nicotine Tob. Res. Off J. Soc. Res. Nicotine Tob."},{"key":"26851_CR32","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1186\/s12889-023-16144-2","volume":"23","author":"S Galmiche","year":"2023","unstructured":"Galmiche, S. et al. Reduction of SARS-CoV-2 intra-household child-to-parent transmission associated with ventilation: results from a case\u2013control study. BMC Public. Health. 23, 1240 (2023).","journal-title":"BMC Public. Health"},{"key":"26851_CR33","doi-asserted-by":"publisher","first-page":"e2417977","DOI":"10.1001\/jamanetworkopen.2024.17977","volume":"7","author":"NB Griffith","year":"2024","unstructured":"Griffith, N. B. et al. Tobacco Use, and COVID-19 outcomes. JAMA Netw. Open. 7, e2417977 (2024). Cannabis.","journal-title":"JAMA Netw. Open."},{"key":"26851_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamainternmed.2020.8360","volume":"181","author":"KE Lowe","year":"2021","unstructured":"Lowe, K. E., Zein, J., Hatipo\u011flu, U. & Attaway, A. Association of smoking and cumulative Pack-Year exposure with COVID-19 outcomes in the Cleveland clinic COVID-19 registry. JAMA Intern. Med. 181, 709\u2013711 (2021).","journal-title":"JAMA Intern. Med."},{"key":"26851_CR35","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1038\/s41467-021-23233-6","volume":"12","author":"S Le Vu","year":"2021","unstructured":"Le Vu, S. et al. Prevalence of SARS-CoV-2 antibodies in france: results from nationwide serological surveillance. Nat. Commun. 12, 3025 (2021).","journal-title":"Nat. Commun."},{"key":"26851_CR36","unstructured":"DREES. Le temps consacr\u00e9 aux activit\u00e9s parentales | Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques. https:\/\/drees.solidarites-sante.gouv.fr\/publications\/etudes-et-resultats\/le-temps-consacre-aux-activites-parentales"},{"key":"26851_CR37","doi-asserted-by":"publisher","first-page":"E1599","DOI":"10.1503\/cmaj.221335","volume":"194","author":"DM Skowronski","year":"2022","unstructured":"Skowronski, D. M. et al. Serial cross-sectional Estimation of vaccine-and infection-induced SARS-CoV-2 Seroprevalence in British Columbia, Canada. CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can. 194, E1599\u2013E1609 (2022).","journal-title":"CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can."},{"key":"26851_CR38","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.lanepe.2022.100547","volume":"24","author":"ME Zaballa","year":"2023","unstructured":"Zaballa, M. E. et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, switzerland: a population-based study. Lancet Reg. Health Eur. 24, 100547 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"26851_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.amjmed.2024.06.002","volume":"137","author":"C de Flor\u00eancio","year":"2024","unstructured":"de Flor\u00eancio, C. et al. Adjunctive Statin therapy in patients with Covid-19: A systematic review and Meta-Analysis of randomized controlled trials. Am. J. Med. 137, 966\u2013973e11 (2024).","journal-title":"Am. J. Med."},{"key":"26851_CR40","doi-asserted-by":"publisher","first-page":"ofae574","DOI":"10.1093\/ofid\/ofae574","volume":"11","author":"MV Zanni","year":"2024","unstructured":"Zanni, M. V. et al. Effects of Pitavastatin on COVID-19 incidence and seriousness among a global cohort of people with HIV. Open. Forum Infect. Dis. 11, ofae574 (2024).","journal-title":"Open. Forum Infect. Dis."},{"key":"26851_CR41","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","volume":"119","author":"CR Dormuth","year":"2009","unstructured":"Dormuth, C. R. et al. Statin adherence and risk of accidents: a cautionary Tale. Circulation 119, 2051\u20132057 (2009).","journal-title":"Circulation"},{"key":"26851_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa2309002","volume":"391","author":"J Hammond","year":"2024","unstructured":"Hammond, J. et al. Oral Nirmatrelvir\u2013Ritonavir as postexposure prophylaxis for Covid-19. N Engl. J. Med. 391, 224\u2013234 (2024).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26851-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:25:54Z","timestamp":1764325554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26851-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26851-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42644"}}